MCID: SYS055
MIFTS: 22

Systemic Lupus Erythematosus 12

Categories: Genetic diseases, Rare diseases, Nephrological diseases, Immune diseases, Bone diseases, Skin diseases

Aliases & Classifications for Systemic Lupus Erythematosus 12

MalaCards integrated aliases for Systemic Lupus Erythematosus 12:

Name: Systemic Lupus Erythematosus 12 54
Systemic Lupus Erythematosus, Susceptibility to, 12 13

Classifications:



External Ids:

OMIM 54 612254

Summaries for Systemic Lupus Erythematosus 12

MalaCards based summary : Systemic Lupus Erythematosus 12, also known as systemic lupus erythematosus, susceptibility to, 12, is related to systemic lupus erythematosus and protein-losing enteropathy. An important gene associated with Systemic Lupus Erythematosus 12 is SLEB12 (Systemic Lupus Erythematosus, Susceptibility To, 12). The drugs Simvastatin and Azathioprine have been mentioned in the context of this disorder. Affiliated tissues include skin, testes and liver.

Description from OMIM: 612254

Related Diseases for Systemic Lupus Erythematosus 12

Symptoms & Phenotypes for Systemic Lupus Erythematosus 12

Clinical features from OMIM:

612254

Drugs & Therapeutics for Systemic Lupus Erythematosus 12

Drugs for Systemic Lupus Erythematosus 12 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 151)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Simvastatin Approved Phase 4,Phase 1,Early Phase 1 79902-63-9 54454
2
Azathioprine Approved Phase 4,Phase 3,Phase 2 446-86-6 2265
3
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 2 128794-94-5 5281078
4
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2 24280-93-1 446541
5 Anticholesteremic Agents Phase 4,Phase 2,Phase 1,Early Phase 1
6 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
7 Calcium, Dietary Phase 4,Phase 1
8 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4,Phase 2,Phase 1,Early Phase 1
9 Hypolipidemic Agents Phase 4,Phase 2,Phase 1,Early Phase 1
10 Lipid Regulating Agents Phase 4,Phase 2,Phase 1,Early Phase 1
11 Rosuvastatin Calcium Phase 4,Phase 1 147098-20-2
12 Estrogens Phase 4
13 Estrogens, Conjugated (USP) Phase 4
14 Hormone Antagonists Phase 4,Phase 3,Phase 2
15 Hormones Phase 4,Phase 3,Phase 2
16 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2
17 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2
18 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2
19 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1
20 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
21 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
22 Neurotransmitter Agents Phase 4,Phase 3,Phase 2
23 Omega 3 Fatty Acid Nutraceutical Phase 4
24
Alendronate Approved Phase 2, Phase 3 121268-17-5, 66376-36-1 2088
25
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
26
Hydroxychloroquine Approved Phase 3,Phase 2 118-42-3 3652
27
Methylprednisolone Approved, Vet_approved Phase 3,Phase 2 83-43-2 6741
28
Prednisolone Approved, Vet_approved Phase 3,Phase 2 50-24-8 5755
29
rituximab Approved Phase 3,Phase 2 174722-31-7 10201696
30
Diphenhydramine Approved Phase 3,Phase 2 58-73-1, 147-24-0 3100
31
Histamine Approved, Investigational Phase 3,Phase 2 75614-87-8, 51-45-6 774
32
Promethazine Approved Phase 3,Phase 2 60-87-7 4927
33
Abatacept Approved Phase 2, Phase 3 332348-12-6 10237
34
Prednisone Approved, Vet_approved Phase 2, Phase 3 53-03-2 5865
35
Acetaminophen Approved Phase 3 103-90-2 1983
36
Infliximab Approved Phase 2, Phase 3 170277-31-3
37
Dehydroepiandrosterone Approved, Nutraceutical Phase 3,Phase 2 53-43-0 9860744
38 Antibodies Phase 3,Phase 2,Phase 1
39 Immunoglobulins Phase 3,Phase 2,Phase 1
40 Antibodies, Monoclonal Phase 3,Phase 2,Phase 1
41 Adjuvants, Immunologic Phase 3,Phase 2
42 glucocorticoids Phase 3,Phase 2
43 Bone Density Conservation Agents Phase 2, Phase 3
44 Heptavalent Pneumococcal Conjugate Vaccine Phase 2, Phase 3
45 Vaccines Phase 2, Phase 3,Phase 1
46 Alkylating Agents Phase 3,Phase 2,Phase 1
47 Antiemetics Phase 3,Phase 2
48 Anti-Infective Agents Phase 3,Phase 2,Phase 1
49 Anti-Inflammatory Agents Phase 3,Phase 2
50 Antineoplastic Agents, Hormonal Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 88)

id Name Status NCT ID Phase Drugs
1 Efficacy and Adverse Effect of Simvastatin Compare to Rosuvastatin in Systemic Lupus Erythematosus (SLE) Patients With Corticosteroid Therapy and High Low-Density Lipoprotein (LDL) Cholesterol Level Unknown status NCT00866229 Phase 4 Rosuvastatin;Simvastatin
2 Effect of Hormone Replacement Therapy on Lupus Activity Completed NCT00392093 Phase 4 Conjugated equine estrogens 0.625 mg/d + MPA 5 mg/d/10d
3 Enteric-coated Mycophenolate Sodium Versus Azathioprine for the Extra-renal Lupus Manifestations Completed NCT01112215 Phase 4 Azathioprine;Enteric-Coated Mycophenolate Sodium
4 Efficacy of Fish Oil in Lupus Patients Completed NCT00828178 Phase 4 Omega-3
5 Effect of Simvastatin on Endothelial Function in Premenopausal Women With Systemic Lupus Erythematosus (0733-271)(TERMINATED) Terminated NCT00739050 Phase 4 simvastatin;Comparator: Placebo
6 The Effect of Milnacipran on Fatigue and Quality of Life in Lupus Patients Withdrawn NCT01359826 Phase 4 Milnacipran
7 Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus (SLE) Completed NCT01261793 Phase 3 Placebo;Epratuzumab;Epratuzumab
8 Study of Epratuzumab Versus Placebo in Subjects With Moderate to Severe General Systemic Lupus Erythematosus Completed NCT01262365 Phase 3 Epratuzumab;Epratuzumab;Placebo
9 Open Label Extension Study of Epratuzumab in Subjects With Systemic Lupus Erythematosus Completed NCT01408576 Phase 3 Epratuzumab;Epratuzumab
10 GL701 (Prestara™) in Women With Systemic Lupus Erythematosus Receiving Treatment With Glucocorticoids Completed NCT00082511 Phase 3 Prasterone (GL701)
11 Alendronate Osteoporosis Study Completed NCT00277251 Phase 2, Phase 3 Alendronate
12 Safety Study of Two Vaccine Strategies in Patients With Systemic Lupus Erythematosus Completed NCT00611663 Phase 2, Phase 3
13 Cyclophosphamide and Hydroxychloroquine for Thrombocytopenia in SLE Recruiting NCT02444728 Phase 3 Hydroxychloroquine;Cyclophosphamide;Azathioprine;Methylprednisolone
14 A 52-Week, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a 200-mcg Dose of IPP-201101 Plus Standard of Care in Patients With Systemic Lupus Erythematosus Active, not recruiting NCT02504645 Phase 3 IPP-201101;Placebo
15 Efficacy and Safety of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus Active, not recruiting NCT02446899 Phase 3 Placebo
16 Efficacy and Safety of Two Doses of Anifrolumab Compared to Placebo in Adult Subjects With Active Systemic Lupus Erythematosus Active, not recruiting NCT02446912 Phase 3 Placebo
17 Trial of Rituximab and Mycophenolate Mofetil Without Oral Steroids for Lupus Nephritis Suspended NCT01773616 Phase 3 Oral prednisolone;Rituximab;Mycophenolate mofetil;Methyl prednisolone
18 A Study of Tabalumab (LY2127399) Using Two Different Injection Methods in Participants With Lupus Terminated NCT02041091 Phase 3 Tabalumab Auto-Injector;Tabalumab Prefilled Syringe
19 A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus Terminated NCT00381810 Phase 3 Rituximab;Methylprednisolone;Acetaminophen;Diphenhydramine
20 Efficacy and Safety Study of Abatacept to Treat Lupus Nephritis Terminated NCT00430677 Phase 2, Phase 3 Corticosteroids (prednisone or prednisolone);Abatacept;Abatacept;Mycophenolate mofetil (MMF);Abatacept
21 TNF Blockade With Remicade in Active Lupus Nephritis WHO Class V (TRIAL ) Terminated NCT00368264 Phase 2, Phase 3 infliximab;placebo
22 Umbilical Cord Mesenchymal Stem Cells for Patients With Primary Biliary Cirrhosis Unknown status NCT01662973 Phase 1, Phase 2
23 Umbilical Cord Mesenchymal Stem Cells for Patients With Autoimmune Hepatitis Unknown status NCT01661842 Phase 1, Phase 2
24 Study Evaluating the Pharmacokinetics and Safety of Epratuzumab in Japanese Systemic Lupus Erythematosus (SLE) Completed NCT01449071 Phase 1, Phase 2
25 Vitamin D3 in Systemic Lupus Erythematosus Completed NCT00710021 Phase 2 Vitamin D3;Vitamin D3 placebo
26 Open Label Extension Study of Epratuzumab in Japanese Systemic Lupus Erythematosus (SLE) Subjects Completed NCT01534403 Phase 2
27 Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus (SLE) Patients With Active Disease Completed NCT00624351 Phase 2
28 Auto-immunity in Lupus Patients After Influenza Vaccine Completed NCT01072734 Phase 2 Vaccine
29 Lymphocyte Depletion and Stem Cell Transplantation to Treat Severe Systemic Lupus Erythematosus Completed NCT00076752 Phase 2 fludarabine phosphate;cyclophosphamide;methylprednisolone;Diphenhydramine;Mesna
30 Pilot Study of Rituximab Therapy for Systemic Lupus Erythematosus (SLE) and Vasculitis Completed NCT00293072 Phase 2 Rituximab
31 Exploratory Study of Changes in Disease Activity and Biomarkers With ABR-215757 in Patients With Mild Active Systemic Lupus Erythematosus (SLE) Completed NCT00997100 Phase 2 paquinimod (ABR-215757)
32 Study of Epratuzumab in Systemic Lupus Erythematosus Completed NCT00383513 Phase 2
33 Psychoeducational Approach to Improve Health in Lupus Completed NCT00000417 Phase 2
34 Open-label Study of Epratuzumab in Serologically-positive Systemic Lupus Erythematosus Patients With Active Disease Completed NCT00660881 Phase 2
35 Prevention of Atherosclerosis and Heart Disease in Patients With Systemic Lupus Erythematosis (SLE) Completed NCT00054938 Phase 2 pravastatin;aspirin;ramipril;Vitamins: B6, B12, and folate
36 Can Targeted Elimination of B-cell Depletion Therapy and/or Combination Therapy on Systemic Lupus Erythematosus Completed NCT00556192 Phase 2 rituximab
37 Laquinimod Study in Systemic Lupus Erythematosus (SLE) Patients With Active Lupus Arthritis Completed NCT01085084 Phase 2 Laquinimod;Laquinimod
38 Drug Therapy in Lupus Nephropathy Completed NCT00001212 Phase 2 prednisone;cyclophosphamide;cyclosporin A
39 Abatacept in the Treatment and Prevention of Active Systemic Lupus Erythematosus (SLE) Flares in Combination With Prednisone Completed NCT00119678 Phase 2 Abatacept;Placebo;Prednisone;Abatacept
40 Dehydroepiandrosterone Administration in Women With Systemic Lupus Erythematosus or Primary Sjögren's Syndrome Completed NCT00391924 Phase 2 Dehydroepiandrosterone
41 Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus Completed NCT01972568 Phase 2 Atacicept 75 milligram (mg);Atacicept 150 mg;Placebo
42 Pilot Study of Thalidomide to Treat Sjogren's Syndrome Completed NCT00001599 Phase 2 Thalidomide
43 A Study to Evaluate Safety and Tolerability of Subcutaneous Doses of MEDI-545 in Subjects With Lupus Completed NCT00657189 Phase 2 MEDI-545;MEDI-545;MEDI-545;MEDI-545;Placebo
44 Subcutaneous Treatment In Randomized Subjects To Evaluate Safety And Efficacy In Generalized Lupus Erythematosus Completed NCT01405196 Phase 2
45 Study of the Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus Erythematosus Recruiting NCT02908100 Phase 2 GDC-0853 (high dose);GDC-0853 (low dose);Placebo
46 Randomized MMF Withdrawal in Systemic Lupus Erythematosus (SLE) Recruiting NCT01946880 Phase 2 Mycophenolate Mofetil;Hydroxychloroquine or Chloroquine;Prednisone
47 ILT-101 in Patients With Active Moderate to Severe Systemic Lupus Erythematosus (SLE) Recruiting NCT02955615 Phase 2 ILT-101;Placebo
48 Study to Evaluate BIIB059 in Cutaneous Lupus Erythematosus (CLE) With or Without Systemic Lupus Erythematosus (SLE) Recruiting NCT02847598 Phase 2 BIIB059;Placebo
49 Clarification of Abatacept Effects in SLE With Integrated Biologic and Clinical Approaches Recruiting NCT02270957 Phase 2
50 Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases Recruiting NCT01988506 Phase 2 Interleukin 2

Search NIH Clinical Center for Systemic Lupus Erythematosus 12

Genetic Tests for Systemic Lupus Erythematosus 12

Anatomical Context for Systemic Lupus Erythematosus 12

MalaCards organs/tissues related to Systemic Lupus Erythematosus 12:

39
Skin, Testes, Liver, Bone, Endothelial, T Cells, B Cells

Publications for Systemic Lupus Erythematosus 12

Articles related to Systemic Lupus Erythematosus 12:

id Title Authors Year
1
Protein-losing enteropathy in systemic lupus erythematosus: 12 years experience from a Chinese academic center. ( 25490025 )
2014

Variations for Systemic Lupus Erythematosus 12

Expression for Systemic Lupus Erythematosus 12

Search GEO for disease gene expression data for Systemic Lupus Erythematosus 12.

Pathways for Systemic Lupus Erythematosus 12

GO Terms for Systemic Lupus Erythematosus 12

Sources for Systemic Lupus Erythematosus 12

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....